# RAISE

Source: https://onco.cc/trials/raise/  
OnCo record `raise` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Switching from one blood-vessel drug to another after progression gave about six extra weeks, the same small gain as aflibercept.

## Summary

RAISE randomised 1,072 patients whose metastatic colorectal cancer had progressed during or within six months of first-line bevacizumab, oxaliplatin and a fluoropyrimidine to second-line FOLFIRI with ramucirumab 8 mg/kg or placebo. Median overall survival was 13.3 against 11.7 months. Ramucirumab blocks VEGF receptor 2 rather than the ligand, and the result shows that continued blockade of the pathway after progression helps a little but does not overcome resistance. It is not funded for colorectal cancer in England.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-24
- Registry id: NCT01183780
- Phase: 3
- Setting: Metastatic colorectal cancer progressing on first-line bevacizumab, oxaliplatin and a fluoropyrimidine: FOLFIRI with ramucirumab or placebo
- Sponsor: Eli Lilly
- Enrolled: 1072
- Result: Median overall survival 13.3 against 11.7 months.
- Outcomes: Overall survival: FOLFIRI plus ramucirumab 13.3 months vs FOLFIRI plus placebo 11.7 months

## Sources

- ClinicalTrials.gov NCT01183780: https://clinicaltrials.gov/study/NCT01183780
- RAISE: ramucirumab with second-line FOLFIRI in metastatic colorectal carcinoma (Lancet Oncology 2015): https://doi.org/10.1016/S1470-2045(15)70127-0

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- drugs: [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Ramucirumab](https://onco.cc/drugs/ramucirumab/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)
- trials: [VELOUR](https://onco.cc/trials/velour/)

---
JSON: https://onco.cc/api/v1/entities/raise.json